- Previous Close
0.8900 - Open
0.8800 - Bid 0.8800 x --
- Ask 0.9900 x --
- Day's Range
0.8800 - 0.8800 - 52 Week Range
0.8400 - 1.4500 - Volume
2,700 - Avg. Volume
1,141 - Market Cap (intraday)
9.184M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2000 - Earnings Date Nov 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
www.medicure.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MPH.V
View MorePerformance Overview: MPH.V
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MPH.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MPH.V
View MoreValuation Measures
Market Cap
9.18M
Enterprise Value
5.22M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.44
Price/Book (mrq)
0.46
Enterprise Value/Revenue
0.25
Enterprise Value/EBITDA
6.66
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.56%
Return on Assets (ttm)
-5.63%
Return on Equity (ttm)
-12.90%
Revenue (ttm)
20.93M
Net Income Avi to Common (ttm)
-2.63M
Diluted EPS (ttm)
-0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
5.85M
Total Debt/Equity (mrq)
2.06%
Levered Free Cash Flow (ttm)
1.45M